Ignite Creation Date:
2025-12-25 @ 12:43 AM
Ignite Modification Date:
2026-03-04 @ 10:12 PM
Study NCT ID:
NCT03322267
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-12-19
First Post:
2017-10-16
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence
Sponsor:
National Taiwan University Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-10-27
Start Date Type:
ACTUAL
Primary Completion Date:
2024-01-31
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-12-30
Completion Date Type:
ESTIMATED
First Submit Date:
2017-10-16
First Submit QC Date:
None
Study First Post Date:
2017-10-26
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-09-11
Results First Submit QC Date:
None
Results First Post Date:
2024-12-19
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-11-27
Last Update Post Date:
2024-12-19
Last Update Post Date Type:
ACTUAL